BioPharma Dive3h
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
Barchart on MSN4h
Is Amgen Stock Underperforming the Dow?
Amgen Inc. (AMGN), incorporated in 1980 and headquartered in Thousand Oaks, California, is a biotech titan that crafts ...
Zacks.com on MSN6h
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?
Amgen’s AMGN stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line ...
Why Amgen’s MariTide could rival Eli Lilly, Novo Nordisk’s obesity drugs
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
ENDPOINTS NEWS11h
On heels of Mar­i­Tide da­ta, Dan­ish obe­si­ty biotech dis­clos­es €80M Se­ries A
Versant is out with its third obesity biotech of the year, leading an €80 million Series A for Antag Therapeutics, a Danish ...